Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **corneal extracellular matrix** is a specialized structure comprising various collagens (primarily type I, V, VI, and XII) and proteoglycans (e.g., keratocan, lumican, decorin, mimecan) that are essential for maintaining corneal transparency, biomechanical strength, and facilitating the passage of light to the retina[1][3]. It forms more than 90% of the corneal thickness and serves as the scaffold for corneal cells, especially keratocytes, which are responsible for continual ECM remodeling during homeostasis and repair. In response to injury or disease, keratocytes become activated and modify the ECM composition, but excessive or disorganized ECM deposition leads to corneal scarring and opacity. Current regenerative therapies focus on using stem cells, bioengineered hydrogels, and decellularized ECM materials to promote proper ECM regeneration, restore clarity, and support nerve and cellular in-growth[1][2][3][4]. "Corneal extracellular matrix regeneration" describes this reparative process, not a discrete target entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Corneal extracellular matrix.